{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:16:26Z","timestamp":1791918986225,"version":"4.3.4"},"reference-count":124,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2018,2,24]],"date-time":"2018-02-24T00:00:00Z","timestamp":1519430400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JHD"],"published-print":{"date-parts":[[2018,2,24]]},"DOI":"10.3233\/jhd-170267","type":"journal-article","created":{"date-parts":[[2018,2,24]],"date-time":"2018-02-24T09:09:12Z","timestamp":1519463352000},"page":"1-16","source":"Crossref","is-referenced-by-count":28,"title":["Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington\u2019s Disease"],"prefix":"10.1177","volume":"7","author":[{"given":"Susanna","family":"Waters","sequence":"first","affiliation":[{"name":"Department of Pharmacology, University of Gothenburg, Gothenburg, Sweden"},{"name":"Integrative Research Laboratories AB, Gothenburg, Sweden"},{"name":"Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joakim","family":"Tedroff","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, Karolinska Institute, Stockholm, Sweden"},{"name":"Integrative Research Laboratories AB, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Ponten","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Klamer","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clas","family":"Sonesson","sequence":"additional","affiliation":[{"name":"Integrative Research Laboratories AB, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Waters","sequence":"additional","affiliation":[{"name":"Integrative Research Laboratories AB, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"issue":"20","key":"10.3233\/JHD-170267_ref1","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1056\/NEJM198611133152006","article-title":"Huntington\u2019s disease. Pathogenesis and management","volume":"315","author":"Martin","year":"1986","journal-title":"N Engl J Med"},{"issue":"6","key":"10.3233\/JHD-170267_ref2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. The Huntington\u2019s Disease Collaborative Research Group","volume":"72","author":"HDCRG","year":"1993","journal-title":"Cell"},{"issue":"1","key":"10.3233\/JHD-170267_ref3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.biocel.2010.10.014","article-title":"Huntington\u2019s disease: From molecular basis to therapeutic advances","volume":"43","author":"Krobitsch","year":"2011","journal-title":"Int J Biochem Cell Biol"},{"issue":"3","key":"10.3233\/JHD-170267_ref4","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.410250315","article-title":"An immunohistochemical investigation of the human neostriatum in Huntington\u2019s disease","volume":"25","author":"Goto","year":"1989","journal-title":"Ann Neurol"},{"issue":"4688","key":"10.3233\/JHD-170267_ref5","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1126\/science.3155875","article-title":"Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington\u2019s disease","volume":"227","author":"Graveland","year":"1985","journal-title":"Science"},{"issue":"1","key":"10.3233\/JHD-170267_ref6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1212\/01.WNL.0000132965.14653.D1","article-title":"Onset and rate of striatal atrophy in preclinical Huntington disease","volume":"63","author":"Aylward","year":"2004","journal-title":"Neurology"},{"issue":"8","key":"10.3233\/JHD-170267_ref7","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/jnnp.2007.128728","article-title":"Detection of Huntington\u2019s disease decades before diagnosis: The Predict-HD study","volume":"79","author":"Paulsen","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.3233\/JHD-170267_ref8","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.nurt.2008.01.003","article-title":"Neuroprotection for Huntington\u2019s disease: Ready, set, slow","volume":"5","author":"Hersch","year":"2008","journal-title":"Neurotherapeutics"},{"issue":"8","key":"10.3233\/JHD-170267_ref9","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1212\/01.WNL.0000086373.32347.16","article-title":"Huntington\u2019s disease: Clinical correlates of disability and progression","volume":"61","author":"Mahant","year":"2003","journal-title":"Neurology"},{"issue":"11","key":"10.3233\/JHD-170267_ref10","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1002\/mds.23136","article-title":"Hypokinesia in Huntington\u2019s disease co-occurs with cognitive and global dysfunctioning","volume":"25","author":"Reedeker","year":"2010","journal-title":"Mov Disord"},{"issue":"10","key":"10.3233\/JHD-170267_ref12","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/0166-2236(89)90074-X","article-title":"The functional anatomy of basal ganglia disorders","volume":"12","author":"Albin","year":"1989","journal-title":"Trends Neurosci"},{"issue":"Pt 1","key":"10.3233\/JHD-170267_ref13","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/brain\/awm275","article-title":"White matter connections reflect changes in voluntary-guided saccades in pre-symptomatic Huntington\u2019s disease","volume":"131","author":"Kloppel","year":"2008","journal-title":"Brain"},{"issue":"9","key":"10.3233\/JHD-170267_ref14","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/mds.20979","article-title":"Diffusion tensor imaging in presymptomatic and early Huntington\u2019s disease: Selective white matter pathology and its relationship to clinical measures","volume":"21","author":"Rosas","year":"2006","journal-title":"Mov Disord"},{"issue":"1","key":"10.3233\/JHD-170267_ref15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1474-4422(10)70276-3","article-title":"Biological and clinical changes in premanifest and early stage Huntington\u2019s disease in the TRACK-HD study: The 12-month longitudinal analysis","volume":"10","author":"Tabrizi","year":"2011","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.3233\/JHD-170267_ref16","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.nbd.2011.02.010","article-title":"Connectivity-based segmentation of the striatum in Huntington\u2019s disease: Vulnerability of motor pathways","volume":"42","author":"Bohanna","year":"2011","journal-title":"Neurobiol Dis"},{"issue":"6","key":"10.3233\/JHD-170267_ref17","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","article-title":"Neuropathological classification of Huntington\u2019s disease","volume":"44","author":"Vonsattel","year":"1985","journal-title":"J Neuropathol Exp Neurol"},{"issue":"4","key":"10.3233\/JHD-170267_ref18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.neuint.2012.01.022","article-title":"Nicotine dynamically modulates dopamine clearance in rat striatum in vivo","volume":"60","author":"Guo","year":"2012","journal-title":"Neurochem Int"},{"issue":"7","key":"10.3233\/JHD-170267_ref19","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1212\/01.wnl.0000204230.16619.d9","article-title":"The association of CAG repeat length with clinical progression in Huntington disease","volume":"66","author":"Rosenblatt","year":"2006","journal-title":"Neurology"},{"issue":"Suppl 2","key":"10.3233\/JHD-170267_ref20","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00019052-200312002-00002","article-title":"Dopamine: A key regulator to adapt action, emotion, motivation and cognition","volume":"16","author":"Nieoullon","year":"2003","journal-title":"Curr Opin Neurol"},{"issue":"2, Part 2","key":"10.3233\/JHD-170267_ref21","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0031-6997(25)07428-9","article-title":"The occurrence, distribution and physiological role of catecholamines in the nervous system","volume":"11","author":"Carlsson","year":"1959","journal-title":"Pharmacol Rev"},{"key":"10.3233\/JHD-170267_ref22","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1600-0773.1963.tb01730.x","article-title":"Effect of Chlorpromazine or Haloperidol on Formation of 3methoxytyramine and Normetanephrine in Mouse Brain","volume":"20","author":"Carlsson","year":"1963","journal-title":"Acta Pharmacol Toxicol"},{"issue":"3","key":"10.3233\/JHD-170267_ref23","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/archpsyc.64.3.327","article-title":"The role of dopamine in the pathophysiology of depression","volume":"64","author":"Dunlop","year":"2007","journal-title":"Arch Gen Psychiatry"},{"issue":"Suppl 1 Pt A","key":"10.3233\/JHD-170267_ref24","doi-asserted-by":"crossref","first-page":"64A","DOI":"10.1097\/00002826-199201001-00035","article-title":"Serotonergic and dopaminergic involvement in ethanol intake","volume":"15","author":"Engel","year":"1992","journal-title":"Clin Neuropharmacol"},{"issue":"Pt 4","key":"10.3233\/JHD-170267_ref25","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1046\/j.1469-7580.2000.19640519.x","article-title":"Functional anatomy of movement disorders","volume":"196","author":"Crossman","year":"2000","journal-title":"J Anat"},{"issue":"2","key":"10.3233\/JHD-170267_ref26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0014-4886(90)90033-O","article-title":"Nigral dopamine type-1 receptors are reduced in Huntington\u2019s disease: A postmortem autoradiographic study using [3H]SCH 0 and correlation with [3H]forskolin binding","volume":"110","author":"Filloux","year":"1990","journal-title":"Exp Neurol"},{"issue":"5","key":"10.3233\/JHD-170267_ref27","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/syn.890020511","article-title":"Organization of dopamine D1 and D2 receptors in human striatum: Receptor autoradiographic studies in Huntington\u2019s disease and schizophrenia","volume":"2","author":"Joyce","year":"1988","journal-title":"Synapse"},{"issue":"Pt 3","key":"10.3233\/JHD-170267_ref28","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/brain\/120.3.503","article-title":"PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington\u2019s disease","volume":"120","author":"Ginovart","year":"1997","journal-title":"Brain"},{"issue":"5","key":"10.3233\/JHD-170267_ref29","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/BF02191583","article-title":"Dopamine D1 receptor number\u2013a sensitive PET marker for early brain degeneration in Huntington\u2019s disease","volume":"243","author":"Sedvall","year":"1994","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"Pt 3","key":"10.3233\/JHD-170267_ref30","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/brain\/118.3.689","article-title":"Striatal D1 and D2 receptor binding in patients with Huntington\u2019s disease and other choreas. A PET study","volume":"118","author":"Turjanski","year":"1995","journal-title":"Brain"},{"issue":"Pt 5","key":"10.3233\/JHD-170267_ref31","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/brain\/awg119","article-title":"Progressive striatal and cortical dopamine receptor dysfunction in Huntington\u2019s disease: A PET study","volume":"126","author":"Pavese","year":"2003","journal-title":"Brain"},{"issue":"2","key":"10.3233\/JHD-170267_ref32","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0306-4522(88)90249-7","article-title":"Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson\u2019s disease and Huntington\u2019s chorea","volume":"25","author":"Waters","year":"1988","journal-title":"Neuroscience"},{"issue":"1","key":"10.3233\/JHD-170267_ref33","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0006-8993(87)91506-X","article-title":"Tyrosine hydroxylase-like immunoreactivity is distributed in the matrix compartment of normal human and Huntington\u2019s disease striatum","volume":"416","author":"Ferrante","year":"1987","journal-title":"Brain Res"},{"issue":"12","key":"10.3233\/JHD-170267_ref34","doi-asserted-by":"crossref","first-page":"6809","DOI":"10.1073\/pnas.120166397","article-title":"Severe deficiencies in dopamine signaling in presymptomatic Huntington\u2019s disease mice","volume":"97","author":"Bibb","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.3233\/JHD-170267_ref35","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1471-4159.2006.03762.x","article-title":"Dopamine release is severely compromised in the R6\/2 mouse model of Huntington\u2019s disease","volume":"97","author":"Johnson","year":"2006","journal-title":"J Neurochem"},{"key":"10.3233\/JHD-170267_ref36","first-page":"148","article-title":"Motor function and dopamine release measurements in transgenic Huntington\u2019s disease model rats","author":"Ortiz","year":"1450","journal-title":"Brain Res"},{"issue":"1","key":"10.3233\/JHD-170267_ref37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbr.2009.06.008","article-title":"In vivo imaging of synaptic function in the central nervous system: I. Movement disorders and dementia","volume":"204","author":"Nikolaus","year":"2009","journal-title":"Behav Brain Res"},{"issue":"3","key":"10.3233\/JHD-170267_ref38","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/1467-9450.00238","article-title":"Dopamine and cognitive functioning: Brain imaging findings in Huntington\u2019s disease and normal aging","volume":"42","author":"Backman","year":"2001","journal-title":"Scand J Psychol"},{"issue":"10","key":"10.3233\/JHD-170267_ref39","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/hbm.21134","article-title":"Extrastriatal dopamine D(2) receptor binding in Huntington\u2019s disease","volume":"32","author":"Esmaeilzadeh","year":"2011","journal-title":"Hum Brain Mapp"},{"issue":"4","key":"10.3233\/JHD-170267_ref40","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1586\/14737175.2015.1025383","article-title":"Dopamine and Huntington\u2019s disease","volume":"15","author":"Schwab","year":"2015","journal-title":"Expert Rev Neurother"},{"issue":"19","key":"10.3233\/JHD-170267_ref41","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJM198005083021916","article-title":"Levodopa and presymptomatic detection of Huntington\u2019s disease\u2013eight-year follow-up","volume":"302","author":"Klawans","year":"1980","journal-title":"N Engl J Med"},{"key":"10.3233\/JHD-170267_ref42","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2147\/NDT.S6430","article-title":"Tetrabenazine: The first approved drug for the treatment of chorea in US patients with Huntington disease","volume":"6","author":"Frank","year":"2010","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.3233\/JHD-170267_ref43","doi-asserted-by":"crossref","first-page":"RRN1260","DOI":"10.1371\/currents.RRN1260","article-title":"An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington\u2019s disease","volume":"3","author":"Burgunder","year":"2011","journal-title":"PLoS Curr"},{"issue":"10","key":"10.3233\/JHD-170267_ref44","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1212\/WNL.31.10.1333","article-title":"Huntington disease: Functional capacities in patients treated with neuroleptic and antidepressant drugs","volume":"31","author":"Shoulson","year":"1981","journal-title":"Neurology"},{"issue":"1","key":"10.3233\/JHD-170267_ref45","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/jnnp.63.1.35","article-title":"Clozapine versus placebo in Huntington\u2019s disease: A double blind randomised comparative study","volume":"63","author":"van Vugt","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.3233\/JHD-170267_ref46","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3233\/JHD-150143","article-title":"Antidopaminergic medication is associated with more rapidly progressive Huntington\u2019s disease","volume":"4","author":"Tedroff","year":"2015","journal-title":"J Huntingtons Dis"},{"issue":"12","key":"10.3233\/JHD-170267_ref47","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1136\/jnnp.2010.209668","article-title":"Observing Huntington\u2019s disease: The European Huntington\u2019s Disease Network\u2019s REGISTRY","volume":"82","author":"Orth","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10.3233\/JHD-170267_ref48","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0166-2236(90)90110-V","article-title":"Primate models of movement disorders of basal ganglia origin","volume":"13","author":"DeLong","year":"1990","journal-title":"Trends Neurosci"},{"issue":"Supplement 3","key":"10.3233\/JHD-170267_ref49","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1016\/S1353-8020(09)70822-3","article-title":"Update on models of basal ganglia function and dysfunction","volume":"15","author":"DeLong","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JHD-170267_ref50","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev-neuro-061010-113641","article-title":"Modulation of striatal projection systems by dopamine","volume":"34","author":"Gerfen","year":"2011","journal-title":"Ann Rev Neurosci"},{"issue":"Pt 8","key":"10.3233\/JHD-170267_ref51","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/brain\/120.8.1315","article-title":"Metabolic correlates of pallidal neuronal activity in Parkinson\u2019s disease","volume":"120","author":"Eidelberg","year":"1997","journal-title":"Brain"},{"issue":"3","key":"10.3233\/JHD-170267_ref52","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1755-5949.2010.00134.x","article-title":"Dopamine and glutamate in Huntington\u2019s disease: A balancing act","volume":"16","author":"Andre","year":"2010","journal-title":"CNS Neurosci Thera"},{"key":"10.3233\/JHD-170267_ref53","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.neuroscience.2011.08.052","article-title":"Pathophysiology of Huntington\u2019s disease: Time-dependent alterations in synaptic and receptor function","volume":"198","author":"Raymond","year":"2011","journal-title":"Neuroscience"},{"issue":"4","key":"10.3233\/JHD-170267_ref54","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1523\/JNEUROSCI.3539-10.2011","article-title":"Differential electrophysiological changes in striatal output neurons in Huntington\u2019s disease","volume":"31","author":"Andre","year":"2011","journal-title":"J Neurosci"},{"key":"10.3233\/JHD-170267_ref55","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.conb.2015.01.020","article-title":"Corticostriatal synaptic adaptations in Huntington\u2019s disease","volume":"33","author":"Plotkin","year":"2015","journal-title":"Curr Opin Neurobiol"},{"key":"10.3233\/JHD-170267_ref56","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3389\/fncir.2013.00019","article-title":"Role of cerebral cortex in the neuropathology of Huntington\u2019s disease","volume":"7","author":"Estrada-Sanchez","year":"2013","journal-title":"Front Neural Circuits"},{"issue":"5-6","key":"10.3233\/JHD-170267_ref57","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.pneurobio.2006.11.001","article-title":"The corticostriatal pathway in Huntington\u2019s disease","volume":"81","author":"Cepeda","year":"2007","journal-title":"Prog Neurobiol"},{"issue":"10","key":"10.3233\/JHD-170267_ref58","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1364-6613(98)01231-5","article-title":"Cognitive functions and corticostriatal circuits: Insights from Huntington\u2019s disease","volume":"2","author":"Lawrence","year":"1998","journal-title":"Trends Cogn Sci"},{"issue":"6","key":"10.3233\/JHD-170267_ref59","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1212\/WNL.0b013e318263c443","article-title":"Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease: Report of the guideline development subcommittee of the American Academy of Neurology","volume":"79","author":"Armstrong","year":"2012","journal-title":"Neurology"},{"issue":"3","key":"10.3233\/JHD-170267_ref60","first-page":"CD006456","article-title":"Therapeutic interventions for symptomatic treatment in Huntington\u2019s disease","author":"Mestre","year":"2009","journal-title":"Cochrane Database Syst Rev (Online)"},{"issue":"3","key":"10.3233\/JHD-170267_ref61","first-page":"CD006455","article-title":"Therapeutic interventions for disease progression in Huntington\u2019s disease","author":"Mestre","year":"2009","journal-title":"Cochrane Database Syst Rev (Online)"},{"issue":"5","key":"10.3233\/JHD-170267_ref62","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/WNF.0b013e3181ebb285","article-title":"Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington\u2019s disease","volume":"33","author":"Lundin","year":"2010","journal-title":"Clin Neuropharmacol"},{"issue":"12","key":"10.3233\/JHD-170267_ref63","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1474-4422(11)70233-2","article-title":"Pridopidine for the treatment of motor function in patients with Huntington\u2019s disease (MermaiHD): A phase 3, randomised, double-blind, placebo-controlled trial","volume":"10","author":"de Yebenes","year":"2011","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.3233\/JHD-170267_ref64","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/mds.25362","article-title":"A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington\u2019s disease","volume":"28","author":"Huntington Study Group HI","year":"2013","journal-title":"Mov Disord"},{"issue":"2","key":"10.3233\/JHD-170267_ref65","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.psychres.2010.04.030","article-title":"Earliest functional declines in Huntington disease","volume":"178","author":"Beglinger","year":"2010","journal-title":"Psychiatry Res"},{"key":"10.3233\/JHD-170267_ref66","doi-asserted-by":"crossref","unstructured":"Kieburtz K , Landwehrmeyer GB , Reilmann R , Savola J , Eyal E , Grachev I , et al. Efficacy, safety, and tolerability of pridopidine in Huntington disease (HD): Results from the phase II, double-blind, placebo-controlled, dose-ranging study, Pride-HD (P2.005). . Neurology. 2017;88(16 Supplement).","DOI":"10.1212\/WNL.88.16_supplement.P2.005"},{"issue":"3","key":"10.3233\/JHD-170267_ref67","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3233\/JHD-170241","article-title":"Safety and exploratory efficacy at 36 months in Open-HART, an open-label extension study of pridopidine in Huntington\u2019s disease","volume":"6","author":"McGarry","year":"2017","journal-title":"J Huntingtons Dis"},{"issue":"Suppl 1","key":"10.3233\/JHD-170267_ref68","first-page":"14","article-title":"Effects of the dopaminergic stabilizer pridopidine on motor symptoms in Huntington\u2019s disease: A meta-analysis","volume":"80","author":"Landwehrmeyer","year":"2011","journal-title":"Clin Genet"},{"issue":"4","key":"10.3233\/JHD-170267_ref69","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1021\/acschemneuro.6b00371","article-title":"In vivo systems response profiling and multivariate classification of CNS active compounds: A structured tool for CNS drug discovery","volume":"8","author":"Waters","year":"2017","journal-title":"ACS Chem Neurosci"},{"issue":"7","key":"10.3233\/JHD-170267_ref70","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrd3480","article-title":"How were new medicines discovered?","volume":"10","author":"Swinney","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"26","key":"10.3233\/JHD-170267_ref71","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1021\/jm9703653","article-title":"New generation dopaminergic agents. 1. Discovery of a novel scaffold which embraces the D2 agonist pharmacophore. Structure-activity relationships of a series of 2-(aminomethyl)chromans","volume":"40","author":"Mewshaw","year":"1997","journal-title":"J Med Chem"},{"issue":"6","key":"10.3233\/JHD-170267_ref72","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1021\/jm901689v","article-title":"Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16)","volume":"53","author":"Pettersson","year":"2010","journal-title":"J Med Chem"},{"issue":"1-3","key":"10.3233\/JHD-170267_ref74","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejphar.2010.07.023","article-title":"In vivo pharmacology of the dopaminergic stabilizer pridopidine","volume":"644","author":"Ponten","year":"2010","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.3233\/JHD-170267_ref75","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3233\/JHD-140108","article-title":"Co-administration of the dopaminergic stabilizer pridopidine and tetrabenazine in rats","volume":"3","author":"Waters","year":"2014","journal-title":"J Huntingtons Dis"},{"issue":"2","key":"10.3233\/JHD-170267_ref76","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1124\/jpet.106.102905","article-title":"The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat","volume":"318","author":"Natesan","year":"2006","journal-title":"J Pharmacol Exp Thera"},{"issue":"5","key":"10.3233\/JHD-170267_ref77","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.pnpbp.2005.03.003","article-title":"The dopaminergic stabilizers (-)-OSUand ACR16 reverse (+)-MK-801-induced social withdrawal in rats","volume":"29","author":"Rung","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"4","key":"10.3233\/JHD-170267_ref78","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.pnpbp.2004.05.004","article-title":"The dopaminergic stabiliser ACR16 counteracts the behavioural primitivization induced by the NMDA receptor antagonist MK-801 in mice: Implications for cognition","volume":"28","author":"Nilsson","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"9","key":"10.3233\/JHD-170267_ref79","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s00702-013-1002-4","article-title":"The dopaminergic stabilizer pridopidine increases neuronal activity of pyramidal neurons in the prefrontal cortex","volume":"120","author":"Gronier","year":"2013","journal-title":"J Neural Trans"},{"issue":"11","key":"10.3233\/JHD-170267_ref80","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1111\/jcmm.12604","article-title":"Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6\/2 mouse model","volume":"19","author":"Squitieri","year":"2015","journal-title":"J Cell Mol Med"},{"key":"10.3233\/JHD-170267_ref81","first-page":"23","volume-title":"Techniques in the Behavioral and Neural Sciences","author":"Westerink","year":"1991"},{"issue":"1","key":"10.3233\/JHD-170267_ref82","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00210-011-0641-y","article-title":"Effects of the dopamine stabilizers (S)-(-)-OSUand ACR16 on prolactin secretion in drug-naive and monoamine-depleted rats","volume":"384","author":"Rung","year":"2011","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"12","key":"10.3233\/JHD-170267_ref83","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1073\/pnas.92.12.5734","article-title":"Somatodendritic expression of an immediate early gene is regulated by synaptic activity","volume":"92","author":"Link","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.3233\/JHD-170267_ref84","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s00702-014-1231-1","article-title":"The dopaminergic stabilizers pridopidine and ordopidine enhance cortico-striatal Arc gene expression","volume":"121","author":"Waters","year":"2014","journal-title":"J Neural Transm"},{"key":"10.3233\/JHD-170267_ref85","unstructured":"Waters S , Tedroff J , Edling M , Svanberg B , Klamer D , Pont\u00e9n H , et al. editors. Pridopidine: Mechanism of action - focus on glutamatergic transmission. 2011; Palm Springs, CA, US."},{"issue":"2","key":"10.3233\/JHD-170267_ref86","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00221-009-1959-2","article-title":"The Arc of synaptic memory","volume":"200","author":"Bramham","year":"2010","journal-title":"Exp Brain Res"},{"issue":"11","key":"10.3233\/JHD-170267_ref87","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0166-2236(00)01926-3","article-title":"Arc mRNA dynamics: Return to sender\u2013the NMDA receptor provides the targeting address for Arc mRNA","volume":"24","author":"Martin","year":"2001","journal-title":"Trends Neurosci"},{"issue":"1","key":"10.3233\/JHD-170267_ref88","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0896-6273(01)00275-6","article-title":"Selective targeting of newly synthesized Arc mRNA to active synapses requires NMDA receptor activation","volume":"30","author":"Steward","year":"2001","journal-title":"Neuron"},{"issue":"7 August 2010","key":"10.3233\/JHD-170267_ref89","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1017\/S1461145709990794","article-title":"Adjunctive a2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission","volume":"13","author":"Marcus","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.3233\/JHD-170267_ref90","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1017\/S1461145706006638","article-title":"Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive a2 adrenoceptor blockade: Experimental evidence","volume":"10","author":"Wadenberg","year":"2007","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.3233\/JHD-170267_ref91","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.neuroscience.2003.11.016","article-title":"A 0 and dihydrexidine inhibit locomotor activity and d-amphetamine induced hyperactivity in rats: A role of inhibitory dopamine D1\/5 receptors in the prefrontal cortex?","volume":"124","author":"Isacson","year":"2004","journal-title":"Neuroscience"},{"issue":"1-3","key":"10.3233\/JHD-170267_ref92","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejphar.2009.11.025","article-title":"The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSUdisplay dopamine D(2) receptor antagonism and fast receptor dissociation properties","volume":"628","author":"Dyhring","year":"2010","journal-title":"Eur J Pharmacol"},{"issue":"2-3","key":"10.3233\/JHD-170267_ref93","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejphar.2007.07.031","article-title":"Differences in agonist\/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912","volume":"574","author":"Tadori","year":"2007","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"10.3233\/JHD-170267_ref94","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/j.1471-4159.2009.06554.x","article-title":"Co-operativity in agonist binding at the D2 dopamine receptor: Evidence from agonist dissociation kinetics","volume":"112","author":"Kara","year":"2010","journal-title":"J Neurochem"},{"issue":"2-3","key":"10.3233\/JHD-170267_ref95","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ejphar.2006.11.016","article-title":"Dopamine partial agonist action of (-)OSUis consistent with dopamine hyperactivity in psychosis","volume":"557","author":"Seeman","year":"2007","journal-title":"Eur J Pharmacol"},{"issue":"10","key":"10.3233\/JHD-170267_ref96","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/syn.20663","article-title":"The dopaminergic stabilizer ASP\/ACR16 selectively interacts with D2(High) receptors","volume":"63","author":"Seeman","year":"2009","journal-title":"Synapse"},{"issue":"4","key":"10.3233\/JHD-170267_ref97","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1046\/j.1471-4159.2003.02239.x","article-title":"Alpha2-adrenoceptor mediated co-release of dopamine and noradrenaline from noradrenergic neurons in the cerebral cortex","volume":"88","author":"Devoto","year":"2004","journal-title":"J Neurochem"},{"issue":"1","key":"10.3233\/JHD-170267_ref98","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1124\/jpet.112.194126","article-title":"Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist","volume":"343","author":"Esbenshade","year":"2012","journal-title":"J Pharmacol Exp Therap"},{"issue":"2","key":"10.3233\/JHD-170267_ref99","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2174\/138945006775515455","article-title":"Serotonin-dopamine interaction as a focus of novel antidepressant drugs","volume":"7","author":"Esposito","year":"2006","journal-title":"Curr Drug Targets"},{"issue":"3","key":"10.3233\/JHD-170267_ref100","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0006-3223(00)00850-7","article-title":"5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex","volume":"48","author":"Rollema","year":"2000","journal-title":"Biol Psychiatry"},{"issue":"2-3","key":"10.3233\/JHD-170267_ref101","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0165-0173(99)00046-6","article-title":"Serotonin model of schizophrenia: Emerging role of glutamate mechanisms","volume":"31","author":"Aghajanian","year":"2000","journal-title":"Brain research Brain Res Rev"},{"issue":"Pt 3","key":"10.3233\/JHD-170267_ref102","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1469-7793.1999.777ab.x","article-title":"On the mechanism of histaminergic inhibition of glutamate release in the rat dentate gyrus","volume":"515","author":"Brown","year":"1999","journal-title":"J Physiol"},{"issue":"Pt 2","key":"10.3233\/JHD-170267_ref103","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1113\/jphysiol.2007.141671","article-title":"alpha2-Noradrenergic receptors activation enhances excitability and synaptic integration in rat prefrontal cortex pyramidal neurons via inhibition of HCN currents","volume":"584","author":"Carr","year":"2007","journal-title":"J Physiol"},{"key":"10.3233\/JHD-170267_ref104","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fnint.2013.00025","article-title":"Serotonin modulation of cortical neurons and networks","volume":"7","author":"Celada","year":"2013","journal-title":"Front Integr Neurosci"},{"issue":"1","key":"10.3233\/JHD-170267_ref105","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/mp.2012.3","article-title":"The dopamine stabilizers ACR16 and (-)-OSUdisplay nanomolar affinities at the [sigma]-1 receptor","volume":"18","author":"Sahlholm","year":"2013","journal-title":"Mol Psychiatry"},{"issue":"18","key":"10.3233\/JHD-170267_ref106","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1093\/hmg\/ddw238","article-title":"Pridopidine activates neuroprotective pathways impaired in Huntington disease","volume":"25","author":"Geva","year":"2016","journal-title":"Hum Mol Genet"},{"issue":"Pt A","key":"10.3233\/JHD-170267_ref107","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.nbd.2016.10.006","article-title":"The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease","volume":"97","author":"Ryskamp","year":"2017","journal-title":"Neurobiol Dis"},{"issue":"1476","key":"10.3233\/JHD-170267_ref108","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.brainres.2012.03.029","article-title":"Interactions between NMDA and dopamine receptors: A potential therapeutic target","author":"Wang","year":"2012","journal-title":"Brain Res"},{"issue":"1","key":"10.3233\/JHD-170267_ref109","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.nurt.2009.10.007","article-title":"Pharmacology of the dopaminergic stabilizer pridopidine (ACR16)","volume":"7","author":"Waters","year":"2010","journal-title":"Neurotherapeutics"},{"key":"10.3233\/JHD-170267_ref110","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1749-6632.2000.tb05180.x","article-title":"Activation of an effector immediate-early gene arc by methamphetamine","volume":"914","author":"Yamagata","year":"2000","journal-title":"Ann N Y Acad Sci"},{"issue":"1-3","key":"10.3233\/JHD-170267_ref111","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejphar.2009.08.019","article-title":"F3, a potential antipsychotic with dopamine D(2)\/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: Influence on immediate-early gene expression in rat prefrontal cortex and striatum","volume":"620","author":"Bruins Slot","year":"2009","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.3233\/JHD-170267_ref112","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.euroneuro.2008.09.001","article-title":"Antipsychotic drugs modulate Arc expression in the rat brain","volume":"19","author":"Fumagalli","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"issue":"Pt 4","key":"10.3233\/JHD-170267_ref113","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/brain\/awn025","article-title":"Cerebral cortex and the clinical expression of Huntington\u2019s disease: Complexity and heterogeneity","volume":"131","author":"Rosas","year":"2008","journal-title":"Brain"},{"issue":"Pt 5","key":"10.3233\/JHD-170267_ref114","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1093\/brain\/113.5.1405","article-title":"Cortical and subcortical glucose consumption measured by PET in patients with Huntington\u2019s disease","volume":"113","author":"Kuwert","year":"1990","journal-title":"Brain"},{"key":"10.3233\/JHD-170267_ref115","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1750-1326-2-8","article-title":"Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington\u2019s disease","volume":"2","author":"Gu","year":"2007","journal-title":"Mol Neurodegener"},{"issue":"6","key":"10.3233\/JHD-170267_ref116","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.neuropharm.2012.06.068","article-title":"Blockade of alpha2-adrenoceptors induces Arc gene expression in rat brain in a glutamate receptor-dependent manner: A combined qPCR, in situ hybridisation and immunocytochemistry study","volume":"63","author":"Serres","year":"2012","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.3233\/JHD-170267_ref117","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.nbd.2012.05.013","article-title":"Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington\u2019s disease mice","volume":"48","author":"Milnerwood","year":"2012","journal-title":"Neurobiol Dis"},{"issue":"10","key":"10.3233\/JHD-170267_ref118","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nrn2911","article-title":"Synaptic versus extrasynaptic NMDA receptor signalling: Implications for neurodegenerative disorders","volume":"11","author":"Hardingham","year":"2010","journal-title":"Nat Rev"},{"issue":"12","key":"10.3233\/JHD-170267_ref119","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/nm.2056","article-title":"Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin","volume":"15","author":"Okamoto","year":"2009","journal-title":"Nat Med"},{"issue":"1","key":"10.3233\/JHD-170267_ref120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jphs.2014.12.005","article-title":"Role of sigma-1 receptors in neurodegenerative diseases","volume":"127","author":"Nguyen","year":"2015","journal-title":"J Pharmacol Sci"},{"issue":"2","key":"10.3233\/JHD-170267_ref121","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1212\/WNL.54.2.452","article-title":"Rate of functional decline in Huntington\u2019s disease. Huntington Study Group","volume":"54","author":"Marder","year":"2000","journal-title":"Neurology"},{"issue":"2","key":"10.3233\/JHD-170267_ref122","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.parkreldis.2012.09.012","article-title":"The influence of gender on phenotype and disease progression in patients with Huntington\u2019s disease","volume":"19","author":"Zielonka","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"10.3233\/JHD-170267_ref123","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/WNL.57.3.397","article-title":"A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington\u2019s disease","volume":"57","author":"Huntington Study G","year":"2001","journal-title":"Neurology"},{"issue":"2","key":"10.3233\/JHD-170267_ref124","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1212\/WNL.0000000000003478","article-title":"A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease","volume":"88","author":"McGarry","year":"2017","journal-title":"Neurology"},{"issue":"6","key":"10.3233\/JHD-170267_ref125","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1212\/WNL.0000000000004209","article-title":"The CREST-E study of creatine for Huntington disease: A randomized controlled trial","volume":"89","author":"Hersch","year":"2017","journal-title":"Neurology"},{"key":"10.3233\/JHD-170267_ref126","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1471-2377-9-62","article-title":"Tetrabenazine as anti-chorea therapy in Huntington disease: An open-label continuation study. Huntington Study Group\/TETRA-HD Investigators","volume":"9","author":"Frank","year":"2009","journal-title":"BMC Neurol"}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JHD-170267","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:57:23Z","timestamp":1777453043000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JHD-170267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,24]]},"references-count":124,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jhd-170267","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,24]]}}}